Search results

2315 results

Sorted by Date . Sort by Relevance

  1. Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

    Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)

  2. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

    Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults

  3. Oesophago-gastric cancer: assessment and management in adults (NG83)

    This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.

  4. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

    Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor

  5. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

    Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

  6. Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

    This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.

  7. Transcutaneous microwave ablation for severe primary axillary hyperhidrosis (IPG601)

    Evidence-based recommendations on transcutaneous microwave ablation for severe primary axillary hyperhidrosis (excessive sweating) in adults

  8. Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure (IPG602)

    Evidence-based recommendations on artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure

  9. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death (IPG603)

    Evidence-based recommendations on subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death

  10. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating Waldenstrom's macroglobulinaemia (non-Hodgkin lymphoma) in adults after at least 1 therapy

  11. Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (IPG598)

    Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults

  12. Processed nerve allografts to repair peripheral nerve discontinuities (IPG597)

    Evidence-based recommendations on processed nerve allografts (specially treated nerves) to repair peripheral nerve discontinuities (bridge gaps)

  13. Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced

  14. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

    Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults

  15. Fractures (complex): assessment and management (NG37)

    This guideline covers assessing and managing pelvic fractures, open fractures and severe ankle fractures (known as pilon fractures and intra-articular distal tibia fractures) in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It aims to reduce deaths and long-term health problems by improving the quality of emergency and urgent care.

  16. Total distal radioulnar joint replacement for symptomatic joint instability or arthritis (IPG595)

    Evidence-based recommendations on total distal radioulnar joint replacement for symptomatic joint instability or arthritis in adults

  17. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

    Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic (secondary) non-squamous non-small-cell lung cancer in adults after

  18. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy

  19. Glaucoma: diagnosis and management (NG81)

    This guideline covers diagnosing and managing glaucoma in people aged 18 and over. It includes recommendations on testing and referral (case-finding) for chronic open angle glaucoma and ocular hypertension, and on effective diagnosis, treatment and reassessment to stop these conditions progressing.

  20. Hysteroscopic sterilisation by insertion of intrafallopian implants (IPG587)

    October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.

  21. Cataracts in adults: management (NG77)

    This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.

  22. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

  23. Hepatitis B (chronic): diagnosis and management (CG165)

    This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

  24. Immunosuppressive therapy for kidney transplant in children and young people (TA482)

    Evidence-based recommendations on immunosuppressive therapy for kidney transplant in children and young people

  25. Child maltreatment: when to suspect maltreatment in under 18s (CG89)

    This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help health professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.

  26. Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults

  27. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee

  28. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (IPG593)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease

  29. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries (IPG594)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries

  30. Faltering growth: recognition and management of faltering growth in children (NG75)

    This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.

  31. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

    Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults

  32. Ab externo canaloplasty for primary open-angle glaucoma (IPG591)

    Evidence-based recommendations on ab externo canaloplasty (widening eye’s main draining canal) for primary open-angle glaucoma (damaged optic nerve)

  33. High-intensity focused ultrasound for symptomatic breast fibroadenoma (IPG592)

    Evidence-based recommendations on high-intensity focused ultrasound for symptomatic breast fibroadenoma (benign/non-cancerous lumps in the breast)

  34. Sepsis: recognition, diagnosis and early management (NG51)

    This guideline covers the recognition, diagnosis and early management of sepsis for all populations. The guideline committee identified that the key issues to be included were: recognition and early assessment, diagnostic and prognostic value of blood markers for sepsis, initial treatment, escalating care, identifying the source of infection, early monitoring, information and support for patients and carers, and training and education.